BioGeometry Joins Hands with Sanyou to Build a New Generation AIGC-Driven Antibody Drug Discovery Platform

BioGeometry, a digital biology pioneer company that specializes in applying generative AI to protein design, recently announced a strategic partnership jointly with Sanyou Bio, a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biologic. Both parties will leverage their respective expertise in generative AI technology and practical experience from target discovery to drug Investigational New Drug (IND) application, to create a next-generation AIGC-driven antibody drug discovery platform. They will jointly promote tripartite cooperation with significant innovative drug companies or biotech firms to enhance the efficiency of new drug R&D and help pharmaceutical R&D enterprises improve their global competitiveness.

In this strategic cooperation, while introducing BioGeometry’ self-developed generative AI antibody design platform (GeoBiologics) to Sanyou, both parties will invest their respective advantageous resources and experience to establish an AI-Wet Lab integrated antibody R&D platform, leveraging BioGeometry’s leading AI dry lab platform with Sanyou’ wet lab capabilities. This collaborative effort aims to the development of more large molecule drug pipelines and the incubation of innovative projects, and to carry out further market development.

Cooperation Signing Ceremony

Sanyou has built a world-leading high-throughput, and integrated innovative antibody drug R&D platform, accumulating the world’s largest antibody library and other technological resources. The antibody library construction platform, centered on nine super-trillion antibody libraries with a total capacity of up to 10 trillion, seamlessly integrates phage display and mammalian cell protein expression technologies. Equipped with fully automated screening and integrated antibody drug R&D capabilities, it is suitable for challenging high-difficulty innovative targets and developing complex new molecules, with a focus on producing highly natural, affinity-rich, superbly developable candidates backed by the company’s extensive wet-lab and data analytics expertise.

As a leader in AI-driven protein design, BioGeometry has developed atomic-level geometric deep learning models that learn from a vast amount of data, effectively saving time and costs in antibody design, improving economic efficiency, and increasing the success rate. Moreover, BioGeometry has achieved a dry-wet lab closed-loop on its generative AI antibody discovery SaaS platform, GeoBiologics. Molecules generated or optimized through AI models are then validated and screened through high-throughput wet-lab experiments, and the experimental data are fed back into the AI model, enhancing the prediction accuracy and confidence of the AI. This iterative process of AI design and wet-lab validation can more efficiently identify functional molecules.

AI-Wet Lab Integration Platfrom

This collaboration leverages BioGeometry’ leading AI large models and deep learning capabilities to enable Sanyou’ antibody drug R&D platform to undergo digital and intelligent transformation. Simultaneously, the synergy of both parties’ strengths, namely the dry-wet lab platform, achieves a positive feedback loop and closure of constantly strengthened AI and wet-lab results, creating a high-performance and high-precision antibody R&D platform that embodies “1+1 creating infinite possibilities”. This platform breaks through the traditional limitations of large-molecule drug R&D, reduces the cost of exploration, promotes more precise candidate drug screening and optimization, accelerates the early drug discovery phase, thus shortening the overall R&D cycle and reducing ineffective or low-efficiency R&D attempts.

Dr. Guojun Lang, founder and CEO of Sanyou, remarked, “BioGeometry’s generative AI technology has helped Sanyou to achieve an intelligent digital transformation of our antibody drug R&D platform, further strengthening our advantages in new drug discovery and preclinical integration. We believe that the AIGC antibody drug discovery platform created through our collaboration with BioGeometry will provide more innovative solutions for new drug R&D enterprises, allowing more new drugs to rapidly progress to preclinical research stages and even enter clinical trials, thereby helping pharmaceutical R&D enterprises enhance their global competitiveness.””

Dr. Jian Tang, founder and CEO of BioGeometry, stated, “We look forward to the dry-wet integrated antibody drug discovery platform created in strong alliance with Sanyou becoming an innovative example for AI-empowered new drug R&D leading the industry, accelerating the comprehensive entry of antibody drug R&D into the era of artificial intelligence. We hope to see more large-molecule drug pipelines incubated and realized through our platform, jointly overcoming more challenges in antibody drug R&D, and making substantive contributions to the progress of global disease treatment.”

About BioGeometry

BioGeometry is a generative AI-driven protein design and R&D platform company committed to providing biomanufacturing solutions to traditional manufacturing industries, achieving green and intelligent transformation. The company constructs generative artificial intelligence (AIGC) large-models to understand the language of life, building multimodal large-models that bridge natural language and protein language to reinvent the process of protein drug discovery and design. Dedicated to creating programmable proteins, BioGeometry applies these innovations in biopharmaceuticals and biomaterial production. By applying their expertise to drug development, BioGeometry addresses traditional challenges in large-molecule drug manufacturing, such as high costs, lengthy processes, low success rates, and difficulties in formulation, thus offering innovative drugs to save patients’ lives.

Founded in 2022 by Dr. Jian Tang, a renowned scientist in AI4Drug and deep learning on graphs, with Turing Award laureate Yoshua Bengio serving as the chief scientific advisor, the company has built two foundational platforms: an AI-driven large molecule drug design platform and high-throughput wet-lab validation, creating a closed-loop system that empowers partners to achieve precise and efficient large molecule drug design and optimization.

Business Cooperation:
Official Website:

About Sanyou Bio

Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biologic drugs. Sanyou has built the 4C business patterns that integrate “differentiated CRO, integrated CDO, innovative CPO and characteristic CRS”, to accomplish the mission “to make the R&D easy for innovative biologics”.

Sanyou has established an integrated innovative biologic drug R&D laboratory with advanced facilities, and has a professional team with the majority holding a Ph.D. or master degree. Sanyou has built three industry-leading innovative technology platforms featured by “super-trillion, integration, and intelligence” , which are comprised of more than 50 sub-platforms with the core innovative super-trillion phage display platform, and supported by platforms of material preparation, biologics discovery, molecule optimization, in vitro and in vivo efficacy, production cell line construction, upstream and downstream process development, preclinical R&D, industrialization development, etc.

Sanyou’s business network has expanded to all parts of the world, including Asia, US and Europe, and established branches in Boston, Philadelphia, San Diego and London. Sanyou has established friendly business relationships with more than 1000 pharmaceutical companies, drug R&D institutions and diagnostics companies worldwide. Sanyou received National-level certification as a high-tech enterprise and a Specialized and Sophisticated enterprise, and passed the ISO9001 quality assurance certification and GB/T intellectual property management system certification.

Official Website: